Test Price
4,800 AED✅ Home Collection Available
HLA DSA-SAB Class II IgG Antibodies with C1q Screen Test in UAE | 4800 AED | 2026 DHA Guidelines
تحليل فحص الأجسام المضادة HLA-DSA-SAB من الفئة الثانية IgG مع فحص C1q في الإمارات | 4800 درهم | معتمد من هيئة الصحة بدبي
🔬 99.9% Diagnostic Sensitivity – ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139)
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy (8 AM - 11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in Result Interpretation – direct access to specialist insights.
Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731
يضمن هذا الفحص المتطور تقييمًا دقيقًا للأجسام المضادة الخاصة بالمتبرع (DSA) من فئة HLA-II مع تحليل قدرتها على تثبيت المتمم (C1q)، مما يساعد في إدارة رفض الطعوم الكلوية وفقًا لأعلى معايير الاعتماد الدولي ومعايير هيئة الصحة بدبي.
Clinical Overview & Test Rationale
The HLA DSA-SAB Class II IgG Antibodies with C1q Screen is a high-resolution Luminex-based single antigen bead (SAB) assay designed to detect donor-specific IgG antibodies against HLA class II (DR, DQ, DP) and assess their complement-fixing capacity via C1q binding. This test is indispensable for pre-transplant immunologic risk assessment, post-transplant antibody-mediated rejection (AMR) monitoring, and guiding immunosuppressive strategies. يوفّر الفحص تحديدًا دقيقًا للأجسام المضادة الموجهة ضد مستضدات HLA-II مع تحليل قدرتها على تنشيط المتمم، مما يمكّن أطباء الكلى وأخصائيي الشيخوخة من تخصيص خطط العلاج المناعي.
| Feature | 🌟 Our Test (C1q-Screened Luminex) | Standard HLA Class II IgG SAB (No C1q) |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity & C1q Binding Specificity | ~95% Sensitivity; no functional complement data |
| Methodology | Luminex X-Map® Single Antigen Bead + C1q Assay (LOINC 93336-2) | Luminex IgG SAB only |
| Turnaround | 10-12 Days (Cold-Chain Logistics) | 14-16 Days |
Physician Insight & Safety Protocol
“As a clinician, I emphasize that while this test provides critical donor-specific antibody data, results must be interpreted alongside clinical findings and biopsy results. Do not discontinue prescribed immunosuppressants without direct medical consultation, as this could jeopardize graft survival. Please contact your transplant specialist immediately if you experience symptoms like fever, reduced urine output, or graft tenderness.”
— Dr. PRABHAKAR REDDY (DHA License: 61713011)
⚠️ Medication Warning: Do not discontinue prescribed immunosuppressants or other maintenance therapy without consulting your treating physician. Altering your medication regimen may precipitate acute rejection or life-threatening complications.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active systemic infection or sepsis; recent live-virus vaccination (within 4 weeks) may cause false-positive C1q binding; known current acute rejection episode under active treatment.
- ER Red Flags: Sudden decrease in urine output (<500 mL/day in adults), severe hypertension refractory to medication, acute graft tenderness with fever, or signs of graft infarction – seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of the C1q-binding assay in determining transplant risk?
The C1q-binding assay identifies complement-fixing donor-specific HLA antibodies, which are strongly associated with antibody-mediated rejection and graft loss, enabling early risk stratification before clinical symptoms appear. By focusing on complement-activating DSA, nephrologists can preemptively adjust immunosuppression, potentially preventing irreversible graft damage.
يُحدد فحص C1q الأجسام المضادة الخاصة بالمتبرع المثبتة للمتمم، والتي ترتبط بقوة بالرفض المناعي الخلطي وفشل الطعم، مما يسمح بتصنيف المخاطر مبكراً حتى قبل ظهور الأعراض.
2. Why is home collection available for this and how is sample integrity maintained?
Home collection is performed by licensed phlebotomists using validated cold-chain protocols that maintain serum stability from venipuncture to laboratory processing, preserving antibody integrity and preventing complement degradation. Samples are transported in temperature-monitored containers directly to our ISO-certified facility, meeting UAE PDPL and cold-chain compliance standards.
تُجرى عملية السحب المنزلي بواسطة فنيين مرخصين وفق بروتوكولات سلسلة تبريد معتمدة، مما يحافظ على استقرار العينة وسلامة الأجسام المضادة حتى وصولها إلى المختبر.
3. Does health insurance cover the 4800 AED cost for HLA DSA testing?
Most UAE insurers cover HLA DSA testing when medically necessary for transplant monitoring; direct billing verification via WhatsApp +971 54 548 8731 ensures pre-authorization and minimizes out-of-pocket expenses. Our team can assist with insurance clearance within 24 hours, in accordance with UAE Federal Decree-Law No. 41 of 2024 and PDPL data privacy requirements.
تغطي معظم شركات التأمين في الإمارات هذا الفحص عند الحاجة الطبية؛ ويتم التحقق من التغطية مباشرة عبر واتساب +971 54 548 8731 لضمان الموافقة المسبقة وتخفيض التكاليف.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians